[go: up one dir, main page]

WO2014066468A8 - Formulation d'anticorps, stable, à faible viscosité - Google Patents

Formulation d'anticorps, stable, à faible viscosité Download PDF

Info

Publication number
WO2014066468A8
WO2014066468A8 PCT/US2013/066313 US2013066313W WO2014066468A8 WO 2014066468 A8 WO2014066468 A8 WO 2014066468A8 US 2013066313 W US2013066313 W US 2013066313W WO 2014066468 A8 WO2014066468 A8 WO 2014066468A8
Authority
WO
WIPO (PCT)
Prior art keywords
stable
low viscosity
antibody
antibody formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/066313
Other languages
English (en)
Other versions
WO2014066468A1 (fr
Inventor
Jared BEE
Paul SANTACROCE
Jiali DU
Mariana Dimitrova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to MX2015004668A priority Critical patent/MX2015004668A/es
Priority to RU2015119547A priority patent/RU2015119547A/ru
Priority to CA2885862A priority patent/CA2885862A1/fr
Priority to CN201380055029.3A priority patent/CN104768578A/zh
Priority to BR112015008186A priority patent/BR112015008186A2/pt
Priority to HK15112690.1A priority patent/HK1211840A1/xx
Priority to AU2013334740A priority patent/AU2013334740A1/en
Priority to JP2015539744A priority patent/JP2015536934A/ja
Priority to SG11201502659YA priority patent/SG11201502659YA/en
Priority to EP13848584.2A priority patent/EP2911693A4/fr
Priority to KR1020157013150A priority patent/KR20150070384A/ko
Priority to HK16102332.5A priority patent/HK1214499A1/zh
Priority to US14/437,585 priority patent/US20150239970A1/en
Publication of WO2014066468A1 publication Critical patent/WO2014066468A1/fr
Publication of WO2014066468A8 publication Critical patent/WO2014066468A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation d'anticorps, stable, à faible viscosité, la formulation comprenant une concentration élevée d'anticorps anti-IL6. Dans certains modes de réalisation, l'invention concerne une formulation d'anticorps, stable, à faible viscosité comprenant environ 50 mg/mL à environ 400 mg/mL d'un anticorps anti-IL6, et de l'arginine, la formulation d'anticorps étant dans une solution aqueuse et ayant une viscosité de moins de 20 cP à 23°C. L'invention concerne également des procédés de fabrication et des procédés d'utilisation de telles formulations d'anticorps.
PCT/US2013/066313 2012-10-25 2013-10-23 Formulation d'anticorps, stable, à faible viscosité Ceased WO2014066468A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX2015004668A MX2015004668A (es) 2012-10-25 2013-10-23 Formulacion estable de anticuerpos de baja viscosidad.
RU2015119547A RU2015119547A (ru) 2012-10-25 2013-10-23 Стабильный низковязкий состав с антителом
CA2885862A CA2885862A1 (fr) 2012-10-25 2013-10-23 Formulation d'anticorps, stable, a faible viscosite
CN201380055029.3A CN104768578A (zh) 2012-10-25 2013-10-23 稳定的低粘度抗体配制品
BR112015008186A BR112015008186A2 (pt) 2012-10-25 2013-10-23 formulação de um anticorpo estável e de baixa viscosidade
HK15112690.1A HK1211840A1 (en) 2012-10-25 2013-10-23 Stable, low viscosity antibody formulation
AU2013334740A AU2013334740A1 (en) 2012-10-25 2013-10-23 Stable, low viscosity antibody formulation
JP2015539744A JP2015536934A (ja) 2012-10-25 2013-10-23 安定した低粘度の抗体製剤
SG11201502659YA SG11201502659YA (en) 2012-10-25 2013-10-23 Stable, low viscosity antibody formulation
EP13848584.2A EP2911693A4 (fr) 2012-10-25 2013-10-23 Formulation d'anticorps, stable, à faible viscosité
KR1020157013150A KR20150070384A (ko) 2012-10-25 2013-10-23 안정한 저점도 항체 제제
HK16102332.5A HK1214499A1 (zh) 2012-10-25 2013-10-23 穩定的低粘度抗體配製品
US14/437,585 US20150239970A1 (en) 2012-10-25 2013-10-23 Stable, Low Viscosity Antibody Formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718379P 2012-10-25 2012-10-25
US61/718,379 2012-10-25

Publications (2)

Publication Number Publication Date
WO2014066468A1 WO2014066468A1 (fr) 2014-05-01
WO2014066468A8 true WO2014066468A8 (fr) 2015-04-09

Family

ID=50545202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/066313 Ceased WO2014066468A1 (fr) 2012-10-25 2013-10-23 Formulation d'anticorps, stable, à faible viscosité

Country Status (13)

Country Link
US (1) US20150239970A1 (fr)
EP (1) EP2911693A4 (fr)
JP (1) JP2015536934A (fr)
KR (1) KR20150070384A (fr)
CN (2) CN104768578A (fr)
AU (1) AU2013334740A1 (fr)
BR (1) BR112015008186A2 (fr)
CA (1) CA2885862A1 (fr)
HK (2) HK1214499A1 (fr)
MX (1) MX2015004668A (fr)
RU (1) RU2015119547A (fr)
SG (1) SG11201502659YA (fr)
WO (1) WO2014066468A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
WO2014186350A1 (fr) * 2013-05-15 2014-11-20 Medimmune Limited Purification de polypeptides produits par recombinaison
CA3198322A1 (fr) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Compositions pharmaceutiques et procedes de fabrication de masses solides comprenant des polypeptides et/ou des proteines
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
ES2600488T3 (es) 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
EP2946766B1 (fr) 2014-05-23 2016-03-02 Ares Trading S.A. Composition pharmaceutique liquide
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
UA122673C2 (uk) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Антитіло, що специфічно зв'язується з людським il-6
EP3294273A4 (fr) * 2015-05-08 2018-12-05 Incube Labs, LLC Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler
BR112018001853A2 (pt) * 2015-07-31 2018-09-25 Astrazeneca Pharmaceuticals Lp métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
KR20240090616A (ko) * 2015-08-19 2024-06-21 아스트라제네카 아베 안정한 항-ｉｆｎａｒ1 제형
JP2019510078A (ja) 2016-02-23 2019-04-11 セセン バイオ， インコーポレイテッド Ｉｌ−６アンタゴニスト製剤およびその使用
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
WO2017180594A1 (fr) * 2016-04-13 2017-10-19 Medimmune, Llc Utilisation d'acides aminés en tant que composés stabilisants dans des compositions pharmaceutiques contenant des concentrations élevées d'agents thérapeutiques à base de protéines
SI3479819T1 (sl) * 2016-06-30 2024-06-28 Celltrion Inc. Stabilen tekoči farmacevtski pripravek
CN109803640B (zh) * 2016-08-10 2022-01-04 赛特瑞恩股份有限公司 稳定的液体抗流感病毒抗体医药调配物
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
CN118359705A (zh) 2016-10-19 2024-07-19 英温拉公司 抗体构建体
EP3554543A4 (fr) * 2016-12-16 2020-09-02 Samsung Bioepis Co., Ltd. Composition aqueuse stable d'anticorps anti-c5
KR102312222B1 (ko) 2016-12-22 2021-10-12 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
TW202444416A (zh) 2017-02-01 2024-11-16 耶魯大學 心臟衰竭及心腎症候群之精準治療
MX2019010282A (es) * 2017-03-01 2020-01-09 Medimmune Ltd Formulacion de anticuerpos monoclonales.
EP3624846B1 (fr) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. Formulations de protéines à haute concentration ayant une viscosité réduite incluant une mixture d'acide nicotinique et tryoptophane
WO2019136312A1 (fr) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression
SG11202011984UA (en) 2018-06-05 2020-12-30 King S College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
PE20210462A1 (es) 2018-07-05 2021-03-08 Bayer Ag METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
WO2020223565A1 (fr) * 2019-05-01 2020-11-05 Corvidia Therapeutics, Inc. Formulation d'anticorps anti-il-6
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CA3211692A1 (fr) * 2020-02-24 2023-09-02 Medimmune, Llc Formulations d'anticorps anti-lipase endotheliale
AU2023229902A1 (en) * 2022-03-07 2024-08-29 Mabxience Research, S.L. Stable formulations for antibodies
WO2025116640A1 (fr) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 Formulation liquide stable sans saccharide d'anticorps anti-il-4rα

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0403964B8 (pt) * 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
SI1960430T1 (sl) * 2005-12-09 2015-01-30 Ucb Pharma, S.A. Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120034212A1 (en) * 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PH12013500672A1 (en) * 2010-10-06 2013-06-03 Regeneron Pharma Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies

Also Published As

Publication number Publication date
RU2015119547A (ru) 2016-12-20
CA2885862A1 (fr) 2014-05-01
EP2911693A4 (fr) 2016-04-27
KR20150070384A (ko) 2015-06-24
WO2014066468A1 (fr) 2014-05-01
CN106421782A (zh) 2017-02-22
AU2013334740A8 (en) 2015-04-09
BR112015008186A2 (pt) 2017-09-19
HK1211840A1 (en) 2016-06-03
US20150239970A1 (en) 2015-08-27
SG11201502659YA (en) 2015-05-28
CN104768578A (zh) 2015-07-08
MX2015004668A (es) 2015-07-23
AU2013334740A1 (en) 2015-04-02
EP2911693A1 (fr) 2015-09-02
HK1214499A1 (zh) 2016-07-29
JP2015536934A (ja) 2015-12-24

Similar Documents

Publication Publication Date Title
WO2014066468A8 (fr) Formulation d'anticorps, stable, à faible viscosité
HK1213174A1 (zh) 穩定的含水依那西普製劑
JO2944B1 (en) Long-acting formulations of insulin
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
NZ725654A (en) High-concentration monoclonal antibody formulations
PH12014502778A1 (en) Antibody formulation
WO2014141152A3 (fr) Formulations d'anticorps à faibles concentrations
EP3626253A3 (fr) Formulations stables de linaclotide
WO2011109365A3 (fr) Formulations concentrées de protéine et leurs utilisations
WO2014039903A3 (fr) Formulations aqueuses stables d'adalimumab
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
NZ628398A (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014086982A3 (fr) Composés métalliques stables, leurs compositions et procédés d'utilisation
MX388893B (es) Formulaciones de anticuerpos estables acuosas.
SG10201803430SA (en) Stable formulation of insulin glulisine
WO2010045281A3 (fr) Formulations aqueuses stables de medicaments insolubles ou peu solubles dans l'eau
MX356126B (es) Uso de estabilizadores de glutamina.
NZ598518A (en) Concentrated polypeptide formulations with reduced viscosity
HK1212978A1 (zh) 芥子酸的新型衍生物
WO2014166836A8 (fr) Formulation de composés d'hormone de croissance
WO2013173803A3 (fr) Formulations d'amoxicilline et de clavulanate de potassium et procédés d'utilisation de celles-ci
EA201791354A2 (ru) Препараты производных пиримидиндиона
WO2014149140A3 (fr) Système d'administration comprenant de l'acide ascorbique stabilisé et d'autres principes actifs
WO2015079415A9 (fr) Dispersion solide de cobicistat amorphe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13848584

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2885862

Country of ref document: CA

ENP Entry into the national phase in:

Ref document number: 2013334740

Country of ref document: AU

Date of ref document: 20131023

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2015539744

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/004668

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 14437585

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015008186

Country of ref document: BR

ENP Entry into the national phase in:

Ref document number: 20157013150

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2013848584

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013848584

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2015119547

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 112015008186

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150413